Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Vax 'dark horse' takes the lead

Posted 23 February 2021 PM

Australia seems to have backed a winner in Novavax, which has signed a monster global supply agreement for 1.1 billion doses, while analysts are calling it "the vaccine to beat".

Although Pfizer and AstraZeneca have long been in the COVID-19 vaccine spotlight, Novavax is emerging as the dark horse, signing a memorandum of understanding with Gavi to provide a whopping 1.1 billion doses of its coronavirus candidate to COVAX, to help ensure equitable global vaccine distribution.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Pfizer vs Humira
Adds to a growing list of adalimumab biosims
Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas